Acute biphenotypic leukaemia

MacroGenics Presents Flotetuzumab Data in Patients with Primary Induction Failure and Early Relapsed Acute Myeloid Leukemia at the 2019 ASH Annual Meeting

Retrieved on: 
Monday, December 9, 2019

Furthermore, the same gene signature was associated with patients more likely to respond to flotetuzumab, supporting the mechanism being exploited by this molecule.

Key Points: 
  • Furthermore, the same gene signature was associated with patients more likely to respond to flotetuzumab, supporting the mechanism being exploited by this molecule.
  • Flotetuzumab, an Investigational CD123 x CD3 Bispecific DART Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients
    Abstract #460: Vadakekolathu, et al.
  • ET to review the flotetuzumab data presented at the ASH Annual Meeting and discuss ongoing clinical development plans.
  • Approximately 40-50% of newly diagnosed patients fail to achieve a complete remission with intensive induction therapy (primary induction failure) or experience disease recurrence after a short remission duration (

Clinical Trials for Acute Myeloid Leukemia (AML) Drug Therapy Advancing With Encouraging Results

Retrieved on: 
Tuesday, October 22, 2019

PALM BEACH, Florida, Oct. 22, 2019 /PRNewswire/ -- There is much research activity in the acute myeloid leukemia (AML) the sector.

Key Points: 
  • PALM BEACH, Florida, Oct. 22, 2019 /PRNewswire/ -- There is much research activity in the acute myeloid leukemia (AML) the sector.
  • A greater understanding of the gene changes that often occur in AML is providing insight into why these cells become abnormal.
  • As researchers have found more of these changes, it is becoming clear that there are many types of AML.
  • Each might have different gene changes that affect how the leukemia will progress and which treatments might be most helpful.

Clinical Trials for Acute Myeloid Leukemia (AML) Drug Therapy Advancing With Encouraging Results

Retrieved on: 
Tuesday, October 22, 2019

PALM BEACH, Florida, Oct. 22, 2019 /PRNewswire/ -- There is much research activity in the acute myeloid leukemia (AML) the sector.

Key Points: 
  • PALM BEACH, Florida, Oct. 22, 2019 /PRNewswire/ -- There is much research activity in the acute myeloid leukemia (AML) the sector.
  • A greater understanding of the gene changes that often occur in AML is providing insight into why these cells become abnormal.
  • As researchers have found more of these changes, it is becoming clear that there are many types of AML.
  • Each might have different gene changes that affect how the leukemia will progress and which treatments might be most helpful.

Biotech Brief: Researchers Looking at New Bundled Treatment Options for Leukemia

Retrieved on: 
Wednesday, July 10, 2019

But the Society says that: "Researchers are now studying the causes, diagnosis, and treatment of acute myeloid leukemia (AML) at many medical centers, university hospitals, and other institutions.

Key Points: 
  • But the Society says that: "Researchers are now studying the causes, diagnosis, and treatment of acute myeloid leukemia (AML) at many medical centers, university hospitals, and other institutions.
  • As researchers have found more of these changes, it is becoming clear that there are many types of AML.
  • Each might have different gene changes that affect how the leukemia will progress and which treatments might be most helpful.
  • Chemotherapy is the main treatment for most types of AML but: " Researchers are now looking at ways to prevent or reverse this resistance by using other drugs along with chemo.

Biotech Brief: Researchers Looking at New Bundled Treatment Options for Leukemia

Retrieved on: 
Wednesday, July 10, 2019

But the Society says that: "Researchers are now studying the causes, diagnosis, and treatment of acute myeloid leukemia (AML) at many medical centers, university hospitals, and other institutions.

Key Points: 
  • But the Society says that: "Researchers are now studying the causes, diagnosis, and treatment of acute myeloid leukemia (AML) at many medical centers, university hospitals, and other institutions.
  • As researchers have found more of these changes, it is becoming clear that there are many types of AML.
  • Each might have different gene changes that affect how the leukemia will progress and which treatments might be most helpful.
  • Chemotherapy is the main treatment for most types of AML but: " Researchers are now looking at ways to prevent or reverse this resistance by using other drugs along with chemo.